Top

Published in:

Open Access 01-12-2024 | Colorectal Cancer | Review

Role of long non-coding RNA ELFN1-AS1 in carcinogenesis

Authors: Zanyar HajiEsmailpoor, Alireza Fayazi, Mohammadhossein Teymouri, Peyman Tabnak

Published in: Discover Oncology | Issue 1/2024

Abstract

As one of the leading causes of death worldwide, cancer significantly burdens patients and the healthcare system. The role of long non-protein coding RNAs (lncRNAs) in carcinogenesis has been extensively studied. The lncRNA ELFN1-AS1 was discovered recently, and subsequent studies have revealed its aberrantly high expression in various cancer tissues. In vitro and in vivo experiments have consistently demonstrated the close association between increased ELFN1-AS1 expression and malignant tumor characteristics, particularly in gastrointestinal malignancies. Functional assays have further revealed the mechanistic role of ELFN1-AS1 as a competitive endogenous RNA for microRNAs, inducing tumor growth, invasive features, and drug resistance. Additionally, the investigation into the clinical implication of ELFN1-AS1 has demonstrated its potential as a diagnostic, therapeutic, and, notably, prognostic marker. This review provides a comprehensive summary of evidence regarding the involvement of ELFN1-AS1 in cancer initiation and development, highlighting its clinical significance.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef

Song Y, Li X, Nie S, Hu Z, Zhou D, Sun D, et al. Extracellular vesicles released by glioma cells are decorated by Annexin A2 allowing for cellular uptake via heparan sulfate. Cancer Gene Ther. 2023;30:1–11.CrossRef

Yan H, Bu P. Non-coding RNA in cancer. Essays Biochem. 2021;65(4):625–39.PubMedPubMedCentralCrossRef

Panni S, Lovering RC, Porras P, Orchard S. Non-coding RNA regulatory networks. Biochim Biophys acta Gene Regul Mech. 2020;1863(6):194417.PubMedCrossRef

HajiEsmailPoor Z, Tabnak P, Ahmadzadeh B, Ebrahimi SS, Faal B, Mashatan N. Role of hedgehog signaling related non-coding RNAs in developmental and pathological conditions. Biomed Pharmacother. 2022;153:113507.PubMedCrossRef

Tabnak P, Mafakheri A, Emsailpoor ZH, Kazemi T, Shekari N. Regulatory interplay between microRNAs and WNT pathway in glioma. Biomed Pharmacother. 2021;143:112187.PubMedCrossRef

Ko N-Y, Chen L-R, Chen K-H. The role of micro RNA and long-non-coding RNA in Osteoporosis. Int J Mol Sci. 2020;21(14):4886.PubMedPubMedCentralCrossRef

Lei M, Zheng G, Ning Q, Zheng J, Dong D. Translation and functional roles of circular RNAs in human cancer. Mol Cancer. 2020;19(1):30.PubMedPubMedCentralCrossRef

Zhang P, Wu W, Chen Q, Chen M. Non-Coding RNAs and their Integrated Networks. J Integr Bioinform. 2019. https://doi.org/10.1515/jib-2019-0027.CrossRefPubMedPubMedCentral

10.

Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018;18(1):5–18.PubMedCrossRef

11.

Akhade VS, Pal D, Kanduri C. Long noncoding RNA: genome organization and mechanism of action. Adv Exp Med Biol. 2017;1008:47–74.PubMedCrossRef

12.

Chi Y, Wang D, Wang J, Yu W, Yang J. Long non-coding RNA in the pathogenesis of cancers. Cells. 2019;8(9):1015.PubMedPubMedCentralCrossRef

13.

Sanchez Calle A, Kawamura Y, Yamamoto Y, Takeshita F, Ochiya T. Emerging roles of long non-coding RNA in cancer. Cancer Sci. 2018;109(7):2093–100.PubMedPubMedCentralCrossRef

14.

Yoon J-H, Abdelmohsen K, Gorospe M. Functional interactions among microRNAs and long noncoding RNAs. Semin Cell Dev Biol. 2014;34:9–14.PubMedCrossRef

15.

Lou Z, Gong Y-Q, Zhou X, Hu G-H. Low expression of miR-199 in hepatocellular carcinoma contributes to tumor cell hyper-proliferation by negatively suppressing XBP1. Oncol Lett. 2018;16(5):6531–9.PubMedPubMedCentral

16.

Sangeeth A, Malleswarapu M, Mishra A, Gutti RK. Long non-coding RNA therapeutics: recent advances and challenges. Curr Drug Targets. 2022;23(16):1457–64.PubMedCrossRef

17.

Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47–62.PubMedCrossRef

18.

Polev DE, Karnaukhova IK, Krukovskaya LL, Kozlov AP. ELFN1-AS1: a novel primate gene with possible microRNA function expressed predominantly in human tumors. Biomed Res Int. 2014;2014:398097.PubMedPubMedCentralCrossRef

19.

Jie Y, Ye L, Chen H, Yu X, Cai L, He W, et al. ELFN1-AS1 accelerates cell proliferation, invasion and migration via regulating miR-497-3p/CLDN4 axis in ovarian cancer. Bioengineered. 2020;11(1):872–82.PubMedPubMedCentralCrossRef

20.

Yang B, Miao S. lncRNA ELFN1-AS1 predicts poor prognosis and promotes tumor progression of non-small cell lung cancer by sponging miR-497. Cancer Biomark. 2022;34(4):637–46.MathSciNetPubMedCrossRef

21.

Huang J, Yuan W, Chen B, Li G, Chen X. lncRNA ELFN1-AS1 upregulates TRIM29 by suppressing miR-211-3p to promote gastric cancer progression. Acta Biochim Biophys Sin. 2023;55(3):484–97.PubMedPubMedCentralCrossRef

22.

Feng W, Zhu R, Ma J, Song H. LncRNA ELFN1-AS1 promotes retinoblastoma growth and invasion via regulating miR-4270/SBK1 Axis. Cancer Manag Res. 2021;13:1067–73.PubMedPubMedCentralCrossRef

23.

Ma G, Li G, Gou A, Xiao Z, Xu Y, Song S, et al. Long non-coding RNA ELFN1-AS1 in the pathogenesis of pancreatic cancer. Ann Transl Med. 2021;9(10):877.PubMedPubMedCentralCrossRef

24.

Li Y, Gan Y, Liu J, Li J, Zhou Z, Tian R, et al. Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer. Signal Transduct Target Ther. 2022;7(1):87.PubMedPubMedCentralCrossRef

25.

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.PubMedCrossRef

26.

Peng P, Luan Y, Sun P, Wang L, Zeng X, Wang Y, et al. Prognostic factors in stage IV colorectal cancer patients with resection of liver and/or pulmonary metastases: a population-based cohort study. Front Oncol. 2022;12:850937.PubMedPubMedCentralCrossRef

27.

Li C, Hong S, Hu H, Liu T, Yan G, Sun D. MYC-induced upregulation of Lncrna ELFN1-AS1 contributes to tumor growth in colorectal cancer via epigenetically silencing TPM1. Mol Cancer Res. 2022;20(11):1697–708.PubMedCrossRef

28.

Lei R, Feng L, Hong D. ELFN1-AS1 accelerates the proliferation and migration of colorectal cancer via regulation of miR-4644/TRIM44 axis. Cancer Biomark. 2020;27(4):433–43.PubMedCrossRef

29.

Jing X, Du L, Shi S, Niu A, Wu J, Wang Y, et al. Hypoxia-induced upregulation of lncRNA ELFN1-AS1 promotes colon cancer growth and metastasis through targeting TRIM14 via sponging miR-191-5p. Front Pharmacol. 2022;13:806682.PubMedPubMedCentralCrossRef

30.

Peng S, Luo Y, Chen L, Dai K, Wang Q. lncRNA ELFN1-AS1 enhances the progression of colon cancer by targeting miR-4270 to upregulate AURKB. Open Med. 2022;17(1):1999–2012.CrossRef

31.

Du Y, Hou Y, Shi Y, Liu J, Li T. Long non-coding RNA ELFN1-AS1 promoted colon cancer cell growth and migration via the miR-191-5p/Special AT-Rich sequence-binding protein 1 Axis. Front Oncol. 2020;10:588360.PubMedCrossRef

32.

Zhai L-Q, Wang X-X, Qu C-X, Yang L-Z, Jia C-M, Shi X-C. A long non-coding RNA, ELFN1-AS1, sponges miR-1250 to upregulate MTA1 to promote cell proliferation, migration and invasion, and induce apoptosis in colorectal cancer. Eur Rev Med Pharmacol Sci. 2021;25(14):4655–67.PubMed

33.

Wu F, Zhang W, Wei H, Ma H, Leng G, Zhang Y. lncRNA ELFN1-AS1 promotes proliferation, migration and invasion and suppresses apoptosis in colorectal cancer cells by enhancing G6PD activity. Acta Biochim Biophys Sin. 2023;55(4):649–60.PubMedPubMedCentralCrossRef

34.

Dong L, Ding C, Zheng T, Pu Y, Liu J, Zhang W, et al. Extracellular vesicles from human umbilical cord mesenchymal stem cells treated with siRNA against ELFN1-AS1 suppress colon adenocarcinoma proliferation and migration. Am J Transl Res. 2019;11(11):6989–99.PubMedPubMedCentral

35.

Han B, He J, Chen Q, Yuan M, Zeng X, Li Y, et al. ELFN1-AS1 promotes GDF15-mediated immune escape of colorectal cancer from NK cells by facilitating GCN5 and SND1 association. Discov Oncol. 2023;14(1):56.PubMedPubMedCentralCrossRef

36.

Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2020;18(3):534–42.

37.

Zhuang S-H, Meng C-C, Fu J-J, Huang J. Long non-coding RNA ELFN1-AS1-mediated ZBTB16 inhibition augments the progression of gastric cancer by activating the PI3K/AKT axis. Kaohsiung J Med Sci. 2022;38(7):621–32.PubMedCrossRef

38.

Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493–502.PubMedPubMedCentralCrossRef

39.

Abbas M, Alqahtani MS, Alshahrani MY, Alabdullh K. Aggressive and drug-resistant pancreatic cancer: challenges and novel treatment approaches. Discov Med. 2022;34(173):158–64.PubMed

40.

Uhlenhopp DJ, Then EO, Sunkara T, Gaduputi V. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol. 2020;13(6):1010–21.PubMedCrossRef

41.

Zhang C, Lian H, Xie L, Yin N, Cui Y. LncRNA ELFN1-AS1 promotes esophageal cancer progression by up-regulating GFPT1 via sponging miR-183-3p. Biol Chem. 2020;401(9):1053–61.PubMedCrossRef

42.

Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.PubMedCrossRef

43.

Corre I, Verrecchia F, Crenn V, Redini F, Trichet V. The osteosarcoma microenvironment: a complex but targetable ecosystem. Cells. 2020;9(4):976.PubMedPubMedCentralCrossRef

44.

Chen S, Zeng J, Huang L, Peng Y, Yan Z, Zhang A, et al. RNA adenosine modifications related to prognosis and immune infiltration in osteosarcoma. J Transl Med. 2022;20(1):228.PubMedPubMedCentralCrossRef

45.

Wang B, Wang X, Li P, Niu X, Liang X, Liu G, et al. Osteosarcoma cell-derived exosomal ELFN1-AS1 mediates macrophage M2 polarization via sponging miR-138-5p and miR-1291 to promote the tumorgenesis of osteosarcoma. Front Oncol. 2022;12:881022.PubMedPubMedCentralCrossRef

46.

Fabian ID, Abdallah E, Abdullahi SU, Abdulqader RA, Adamou Boubacar S, Ademola-Popoola DS, et al. Global retinoblastoma presentation and analysis by national income level. JAMA Oncol. 2020;6(5):685–95.PubMedCrossRef

47.

Chantada G, Fandiño A, Manzitti J, Urrutia L, Schvartzman E. Late diagnosis of retinoblastoma in a developing country. Arch Dis Child. 1999;80(2):171–4.PubMedPubMedCentralCrossRef

48.

Chawla B, Hasan F, Azad R, Seth R, Upadhyay AD, Pathy S, et al. Clinical presentation and survival of retinoblastoma in Indian children. Br J Ophthalmol. 2016;100(2):172–8.PubMedCrossRef

49.

Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis the Rosetta Stone of a hidden RNA language? Cell. 2011;146(3):353–8.PubMedPubMedCentralCrossRef

50.

Du Z, Sun T, Hacisuleyman E, Fei T, Wang X, Brown M, et al. Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancer. Nat Commun. 2016;7:10982.ADSPubMedPubMedCentralCrossRef

51.

Zhou L, Zhang Q, Deng H, Ou S, Liang T, Zhou J. The SNHG1-centered ceRNA network regulates cell cycle and is a potential prognostic biomarker for hepatocellular carcinoma. Tohoku J Exp Med. 2022;258(4):265–76.PubMedCrossRef

52.

Cui Y, Wang X, Lin F, Li W, Zhao Y, Zhu F, et al. MiR-29a-3p improves acute lung injury by reducing alveolar epithelial cell PANoptosis. Aging Dis. 2022;13(3):899.PubMedPubMedCentralCrossRef

53.

Wu X, Sui Z, Zhang H, Wang Y, Yu Z. Integrated analysis of lncRNA-mediated ceRNA network in lung adenocarcinoma. Front Oncol. 2020;10:554759.PubMedPubMedCentralCrossRef

54.

Wang L, Cho KB, Li Y, Tao G, Xie Z, Guo B. Long noncoding RNA (lncRNA)-mediated competing endogenous RNA networks provide novel potential biomarkers and therapeutic targets for colorectal cancer. Int J Mol Sci. 2019;20(22):5758.PubMedPubMedCentralCrossRef

55.

Braga EA, Fridman MV, Moscovtsev AA, Filippova EA, Dmitriev AA, Kushlinskii NE. LncRNAs in ovarian cancer progression, metastasis, and main pathways: ceRNA and alternative mechanisms. Int J Mol Sci. 2020;21(22):8855.PubMedPubMedCentralCrossRef

56.

Shi Y, Liu J-B, Deng J, Zou D-Z, Wu J-J, Cao Y-H, et al. The role of ceRNA-mediated diagnosis and therapy in hepatocellular carcinoma. Hereditas. 2021;158(1):44.PubMedPubMedCentralCrossRef

57.

Duffy MJ, O’Grady S, Tang M, Crown J. MYC as a target for cancer treatment. Cancer Treat Rev. 2021;94:102154.PubMedCrossRef

58.

Sugiura R, Satoh R, Takasaki T. ERK: a double-edged sword in cancer. ERK-dependent apoptosis as a potential therapeutic strategy for cancer. Cells. 2021;10(10):2509.PubMedPubMedCentralCrossRef

59.

Samson SC, Khan AM, Mendoza MC. ERK signaling for cell migration and invasion. Front Mol Biosci. 2022;9:998475.PubMedPubMedCentralCrossRef

60.

Patra KC, Hay N. The pentose phosphate pathway and cancer. Trends Biochem Sci. 2014;39(8):347–54.PubMedPubMedCentralCrossRef

61.

Jiang P, Du W, Wu M. Regulation of the pentose phosphate pathway in cancer. Protein Cell. 2014;5(8):592–602.PubMedPubMedCentralCrossRef

62.

Zhao J, Liu Y, Zhu L, Li J, Liu Y, Luo J, et al. Tumor cell membrane-coated continuous electrochemical sensor for GLUT1 inhibitor screening. J Pharm Anal. 2023. https://doi.org/10.1016/j.jpha.2023.04.015.CrossRefPubMedPubMedCentral

63.

Li M, Wei J, Xue C, Zhou X, Chen S, Zheng L, et al. Dissecting the roles and clinical potential of YY1 in the tumor microenvironment. Front Oncol. 2023;13:1122110.PubMedPubMedCentralCrossRef

64.

Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 2014;4:64.PubMedPubMedCentralCrossRef

65.

Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–96.PubMedPubMedCentralCrossRef

66.

Zhang Y, Weinberg RA. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. Front Med. 2018;12(4):361–73.PubMedPubMedCentralCrossRef

67.

Nieto MA, Huang RY-J, Jackson RA, Thiery JP. EMT: 2016. Cell. 2016;166(1):21–45.PubMedCrossRef

68.

Machuca-Aguado J, Rodríguez-Zarco E, Carrero-García B, Vázquez-Ramírez FJ. Metastasis of uveal melanoma in bladder: presentation of two cases and review of the literature. Arch Esp Urol. 2022;75(10):873–7.PubMedCrossRef

69.

Wang X, Blom J, Ye W, Yin L. Estimating and testing the influence of early diagnosis on cancer survival via point effects of diagnoses and treatments. Stat Methods Med Res. 2022;31(8):1538–48.MathSciNetPubMedPubMedCentralCrossRef

70.

Huang H, Wu N, Liang Y, Peng X, Shu J. SLNL: a novel method for gene selection and phenotype classification. Int J Intell Syst. 2022;37(9):6283–304.CrossRef

71.

Tsimberidou A-M. Targeted therapy in cancer. Cancer Chemother Pharmacol. 2015;76(6):1113–32.PubMedPubMedCentralCrossRef

72.

Liu L, Huo S, Liu J, Li Q, Wang J. Metabolic reprogramming of myeloid-derived suppressor cells in the tumor microenvironment. Discov Med. 2021;31(164):141–6.PubMed

73.

Haider T, Pandey V, Banjare N, Gupta PN, Soni V. Drug resistance in cancer: mechanisms and tackling strategies. Pharmacol Rep. 2020;72(5):1125–51.PubMedCrossRef

74.

Qiu Y, Li H, Zhang Q, Qiao X, Wu J. Ferroptosis-related long noncoding RNAs as prognostic marker for colon adenocarcinoma. Appl bionics Biomech. 2022;2022:5220368.PubMedPubMedCentralCrossRef

75.

Chang Q-Q, Chen C-Y, Chen Z, Chang S. LncRNA PVT1 promotes proliferation and invasion through enhancing Smad3 expression by sponging miR-140-5p in cervical cancer. Radiol Oncol. 2019;53(4):443–52.PubMedPubMedCentralCrossRef

76.

Liu J, Liu Y, Gao F, Zhang J, Pan J, Liu Y, et al. Comprehensive study of a novel immune-related lncRNA for prognosis and drug treatment of cervical squamous cell carcinoma. Am J Transl Res. 2021;13(10):11771–85.PubMedPubMedCentral

77.

Chen W, Chen Y, Liu L, Wu Y, Fu P, Cao Y, et al. Comprehensive analysis of immune infiltrates of ferroptosis-related long noncoding RNA and prediction of colon cancer patient prognoses. J Immunol Res. 2022;2022:9480628.PubMedPubMedCentralCrossRef

78.

Zhang W, Fang D, Li S, Bao X, Jiang L, Sun X. Construction and validation of a novel ferroptosis-related lncRNA signature to predict prognosis in colorectal cancer patients. Front Genet. 2021;12:709329.PubMedPubMedCentralCrossRef

79.

Yang W, Ding N, Luo R, Zhang Q, Li Z, Zhao F, et al. Exosomes from young healthy human plasma promote functional recovery from intracerebral hemorrhage via counteracting ferroptotic injury. Bioact Mater. 2023;27:1–14.PubMedPubMedCentral

80.

Qin F, Xu H, Wei G, Ji Y, Yu J, Hu C, et al. A prognostic model based on the immune-related lncRNAs in colorectal cancer. Front Genet. 2021;12:658736.PubMedPubMedCentralCrossRef

81.

He Y, Zhou H, Xu H, You H, Cheng H. Construction of an immune-related lncRNA signature that predicts prognosis and immune microenvironment in osteosarcoma patients. Front Oncol. 2022;12:769202.PubMedPubMedCentralCrossRef

82.

Wang X, Lu Y, Liu Z, Zhang Y, He Y, Sun C, et al. A 9-LncRNA signature for predicting prognosis and immune response in diffuse large B-cell lymphoma. Front Immunol. 2022;13:813031.PubMedPubMedCentralCrossRef

83.

Yang S, Zhou J, Chen Z, Sun Q, Zhang D, Feng Y, et al. A novel m7G-related lncRNA risk model for predicting prognosis and evaluating the tumor immune microenvironment in colon carcinoma. Front Oncol. 2022;12:934928.PubMedPubMedCentralCrossRef

84.

Cao L, Ma X, Rong P, Zhang J, Yang M, Wang W. Comprehensive analysis of DNA methylation and transcriptome to identify PD-1-negative prognostic methylated signature in endometrial carcinoma. Dis Markers. 2022;2022:3085289.PubMedPubMedCentralCrossRef

85.

Chen S, Zhu J, Zhi X. A novel pyroptosis-associated long noncoding RNA signature to predict the prognosis of patients with colorectal cancer. Int J Gen Med. 2021;14:6111–23.PubMedPubMedCentralCrossRef

86.

Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X. Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther. 2021;6(1):128.PubMedPubMedCentralCrossRef

87.

Jia Y, Chen Y, Liu J. Prognosis-predictive signature and nomogram based on autophagy-related long non-coding RNAs for hepatocellular Carcinoma. Front Genet. 2020;11:608668.PubMedPubMedCentralCrossRef

88.

Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol. 2010;221(1):3–12.PubMedPubMedCentralCrossRef

Title: Role of long non-coding RNA ELFN1-AS1 in carcinogenesis
Authors: Zanyar HajiEsmailpoor
Alireza Fayazi
Mohammadhossein Teymouri
Peyman Tabnak
Publication date: 01-12-2024
Publisher: Springer US
Keywords: Colorectal Cancer
Colorectal Cancer
Published in: Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-024-00929-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

MiR-6839-5p inhibits cell proliferation, migration and invasion; a possible correlation with the suppressing VEGFA expression in human chondrosarcoma cells

Molecular mechanism of MLCK1 inducing 5-Fu resistance in colorectal cancer cells through activation of TNFR2/NF-κB pathway

Protosappanin B enhances the chemosensitivity of 5-fluorouracil in colon adenocarcinoma by regulating the LINC00612/microRNA-590-3p/Golgi phosphoprotein 3 axis

A prognostic model for overall survival in recurrent glioma patients treated with bevacizumab-containing therapy

Analysis of clinical characteristics, treatment patterns, and outcome of patients with bilateral testicular germ cell tumors

A novel cholesterol metabolism-related ferroptosis pathway in hepatocellular carcinoma

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials